Do You Offer Adjuvant Chemotherapy And/or Radiotherapy For Patients ...

Register

• Community
  • Overview
  • Experts
  • Editors
  • Fellows
  • Code of conduct
  • AI Guidelines for Physicians
• Company
  • About Us
  • FAQs
  • Privacy Policy
  • Terms of Use
  • Careers
  • Programs
• News
  • News Releases
  • Press Coverage
  • Publications
  • Blog
• Contact Us
• Sign in

Please select the option that best describes you:

Topics: Thoracic Malignancies • Medical Oncology • NCI-CCC Tumor Board Question • Indiana University Do you offer adjuvant chemotherapy and/or radiotherapy for patients with resected atypical carcinoid of the lung with positive mediastinal lymph nodes (T3N2M0)? Answer from: Medical Oncologist at Academic Institution I usually offer 4 cycles of adjuvant therapy with cisplatin plus etoposide for patients with surgically resected T3N2 atypical carcinoid tumor. Atypical carcinoid have intermediate chemosensitivity between typical carcinoid tumors and small cell carcinomas. I do not offer adjuvant therap... Sign In or Register to read more 4503

Related Questions

Would you change systemic therapy in a patient with SCLC with stable systemic disease but CNS progression?

What would you offer to a patient with musculoskeletal pain from tarlatamab, requiring hospitalization and opioid use?

How do you approach duration of immunotherapy in patients with metastatic NSCLC?

How, if at all, are you modifying your practice and clinical workflow for patients receiving checkpoint inhibitors with data showing improved outcomes for patients receiving infusions earlier in the day?

How do you approach treatment selection among novel bispecific antibodies and ADCs for patients with EGFR+ NSCLC previously treated with 3rd generation EGFR inhibitors?

After the MAJESTEC-3 results, and once approved, what is your approach to choosing between tec-dara vs. cilta-cel versus another triplet for multiple myeloma in first relapse?

How do you determine your next line of therapy In ALK+ metastatic NSCLC patients who have widespread progression on first-line lorlatinib?

Does receipt of chemoimmunotherapy for LS-SCLC impact your recommendation for PCI?

If you are using talquetamab as bridging before BCMA CAR-T therapy, when do you assess for response and/or stop the talquetamab?

In light of data from TRIANGLE, ECHO, and ENRICH, what is the best strategy to treat newly diagnosed patients with the blastoid variant MCL?

Copyright © 2026 theMednet All Rights Reserved.